Article

Axi-Cel Responses Sustained With Longer Follow-Up for NHL

Author(s):

Axi-cel (axicabtagene ciloleucel; Yescarta) maintained a complete remission rate of 40% with a median follow-up of 15.4 months for patients with refractory, aggressive non-Hodgkin lymphoma.

Sattva S. Neelapu, MD

Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center

Sattva S. Neelapu, MD

Axi-cel (axicabtagene ciloleucel; Yescarta) maintained a complete remission (CR) rate of 40% with a median follow-up of 15.4 months for patients with refractory, aggressive non-Hodgkin lymphoma (NHL), according to updated findings from the pivotal ZUMA-1 trial presented at the 2017 ASH Annual Meeting.

In the updated assessment, 42% of patients treated with axi-cel remained progression-free and 56% remained alive. The 18-month progression-free survival (PFS) rate was 41% and the 18-month overall survival (OS) rate was 52%. At the time of the analysis, the median duration of response for those achieving a CR was not yet reached.

“Long-term follow-up of ZUMA-1 confirms that these responses can be durable and the ongoing responses at 24 months suggest that late relapses are uncommon. Patients who are in remission at 6 months tend to stay in remission,” lead study author Sattva S. Neelapu, MD, professor at The University of Texas MD Anderson Cancer Center, said in a statement. “With existing therapy, the median survival for people with this disease is only 6 months. Here, we see more than half of patients—59%—are still alive over a year after treatment.”

One hundred eight patients were available for the updated assessment, consisting of 101 from the phase II portion of the trial and 7 from the phase I group. In phase II, patients were enrolled into 2 cohorts consisting of those with diffuse large B-cell lymphoma (n = 77) and those with primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL transformed from follicular lymphoma (TFL; n = 24).

Prior to infusion of axi-cel, a conditioning regimen of fludarabine (30 mg/m2) and cyclophosphamide (500 mg/m2) was administered for 3 days. Axi-cel was administered as a single infusion of modified autologous T cells at a target dose of 2 x 106 CAR-positive T cells/kg. The treatment was manufactured successfully for 99% of patients, and 91% of patients received treatment with the CAR T-cell therapy.

For the 108 patients in the combined analysis, the median age of patients was 58 years (range, 23-76) and 25% were 65 or older. All patients had chemorefractory disease and 70% of patients had received ≥3 prior therapies. Forty-four percent of patients had an IPI score of 3 or 4 and 83% had stage III/IV disease. Overall, 74% of patients were refractory to their second- or later-line of therapy, with 65% having progressive disease as their best response to prior treatment. Twenty-three percent relapsed on prior autologous stem cell transplant (ASCT).

In the combined assessment for best response achieved, the objective response rate (ORR) with axi-cel was 82%, with a CR rate of 58%. In the ongoing cohort at 15.4 months, the ORR was 42% and the CR rate was 40%. In the primary cohort of 101 patients alone, the ongoing ORR was 44% and the CR rate was 39%. The median time for conversation from a partial response (PR) to a CR was 54 days (range, 49-424).

The median duration of ORR was 11.1 months. Forty-three percent of patients from the phase I cohort had a CR at 24 months. The median duration of PR was 1.9 months. The median PFS was 5.8 months, with a 12-month PFS rate of 44%. The median OS had not been reached, with a 12-month OS rate of 59%.

"There is a plateauing of the OS curve at the 16-month time point. The median OS has not yet been reached," said Neelapu. "Durable responders were observed with and without detectable persistent CAR T cells."

There were no new cases of cytokine release syndrome (CRS), neurotoxicity, or grade 5 adverse events (AEs), since the primary assessment, Neelapu noted. In the combined cohort, grade ≥3 AEs were experienced by 97% of patients and grade ≥3 serious AEs were seen in 46% of patients. At the 15.4-month assessment, grade ≥3 CRS was experienced by 12% of patients and grade ≥3 neurotoxicity was seen in 31% of patients. Four percent of patients had a grade 5 AE.

Most patients experienced B cell aplasia and hypogammaglobulinemia, with 8% receiving IVIG during the study. The most common grade ≥3 AEs were neutropenia (79%), anemia (45%), and thrombocytopenia (40%). Infections were the most common new-onset serious AE seen in the extended analysis. These events occurred in 8 patients.

"Late onset AEs were primarily infections and manageable," said Neelapu. "There was no late-onset CRS or neurologic events due to anti-CD19 CAR T cells. No replication-competent retrovirus or insertional mutagenesis was observed."

In October 2017, the FDA approved axi-cel as a treatment for adults with relapsed or refractory NHL, based on findings form the ZUMA-1 trial. The European Medicines Agency is currently reviewing a marketing authorization application for axi-cel for patients with DLBCL. A decision is anticipated in the first half of 2018.

Neelapu SS, Locke FL, Bartlett NL, et al. Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2017; Atlanta. Abstract 578.

Related Videos
Priya U. Kumthekar, MD
David Schiff, MD
Timothy Gershon, MD, PhD
Jordan Hansford, MD
J. Bradley Elder, MD
Rimas V. Lukas, MD
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Minoo Battiwalla, MD, MS
Paolo Caimi, MD